Novartis Gleevec first-line approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA approves Novartis' tyrosine kinase inhibitor Gleevec (imatinib) Dec. 20 for first-line treatment of patients with Philadelphia chromosome positive chronic myeloid leukemia. Approval is based on 12-month data from the confirmatory International Randomized Study of Interferon vs. STI571 (IRIS) comparing Gleevec with the traditional CML regimen of interferon-alpha and cytosine arabinoside (Pharmaceutical Approvals Monthly, July 1, 2002, In Brief). Recently presented 18-month data showed an advantage in complete and major cytogenetic response and in progression-free survival. Data will be extrapolated to support a potentially imminent pediatric CML indicatio
You may also be interested in...
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech Keeps Commitment To External Cancer Innovation
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: